A Randomized, Double Blind, Two-period Cross-over Trial Investigating the Effect of Liraglutide as Add on to Intensive Insulin Treatment on the Endogenous Glucose Production in Subjects With C-peptide Positive Type 1 Diabetes Mellitus

Registration

Registration

NCT02408705

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE2

Masking

TRIPLE

Status

COMPLETED

Enrollment

14

Start

2015-01

Primary completion

2016-05

Lead sponsor

Medical University of Graz

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG:Liraglutide; DRUG:Placebo; DRUG:Mixed Meal Tolerance Test with paracetamol

Results posted

FALSE

Registered primary outcomes

• Area under the curve of the endogenous glucose production from (=EGP) from begin of the hypoglycaemic clamp 5.5 mmol/L period until the end of recovery period (4.0 mmol/L), calculated from stable isotope labelled plasma glucose [After 12 weeks and 2 days of treatment in each treatment period (day 86 and day 198)]